EA200971073A1 - Применение ранолазина при повышенном уровне натрийуретического пептида мозгового типа - Google Patents

Применение ранолазина при повышенном уровне натрийуретического пептида мозгового типа

Info

Publication number
EA200971073A1
EA200971073A1 EA200971073A EA200971073A EA200971073A1 EA 200971073 A1 EA200971073 A1 EA 200971073A1 EA 200971073 A EA200971073 A EA 200971073A EA 200971073 A EA200971073 A EA 200971073A EA 200971073 A1 EA200971073 A1 EA 200971073A1
Authority
EA
Eurasian Patent Office
Prior art keywords
ranolazine
peptide
naturauretic
application
increased level
Prior art date
Application number
EA200971073A
Other languages
English (en)
Inventor
Брент Блэкбёрн
Маркус Йерлинг
Эндрю Волф
Original Assignee
Джилид Пало Альто, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Джилид Пало Альто, Инк. filed Critical Джилид Пало Альто, Инк.
Publication of EA200971073A1 publication Critical patent/EA200971073A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin

Abstract

Настоящее изобретение направлено на применение ранолазина для уменьшения риска неблагоприятных коронарных событий у пациентов, представляющих собой млекопитающих. Как правило, натрийуретический пептид связан с ишемической болезнью сердца, острым коронарным синдромом и/или диастолической дисфункцией. Ранолазин может быть введен указанному пациенту в виде раствора для внутривенного введения или в виде пероральной дозы.
EA200971073A 2007-05-31 2008-03-24 Применение ранолазина при повышенном уровне натрийуретического пептида мозгового типа EA200971073A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94121007P 2007-05-31 2007-05-31
PCT/US2008/058063 WO2008150565A2 (en) 2007-05-31 2008-03-24 Ranolazine for elevated brain-type natriuretic peptide

Publications (1)

Publication Number Publication Date
EA200971073A1 true EA200971073A1 (ru) 2010-08-30

Family

ID=39929825

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200971073A EA200971073A1 (ru) 2007-05-31 2008-03-24 Применение ранолазина при повышенном уровне натрийуретического пептида мозгового типа

Country Status (12)

Country Link
US (1) US20080299195A1 (ru)
EP (1) EP2170333B1 (ru)
KR (1) KR20100033490A (ru)
CN (1) CN101896181A (ru)
CA (1) CA2689633A1 (ru)
EA (1) EA200971073A1 (ru)
EC (1) ECSP099828A (ru)
ES (1) ES2402675T3 (ru)
HK (1) HK1143066A1 (ru)
IL (1) IL202493A0 (ru)
WO (1) WO2008150565A2 (ru)
ZA (1) ZA200908657B (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
WO2003099281A2 (en) 2002-05-21 2003-12-04 Cv Therapeutics, Inc. Administration of a partial fatty acid inhibitor such as ranolazine for the treatment of diabetes
WO2008101008A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of coronary microvascular diseases
EP2117550A1 (en) * 2007-02-13 2009-11-18 CV Therapeutics Inc. Use of ranolazine for the treatment of non-coronary microvascular diseases
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
EP2117509A1 (en) * 2007-02-13 2009-11-18 CV Therapeutics Inc. Use of ranolazine for the treatment of cardiovascular diseases
WO2008116083A1 (en) * 2007-03-22 2008-09-25 Cv Therapeutics, Inc. Use of ranolazine for elevated brain-type natriuretic peptide
US20090012103A1 (en) * 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds
AU2010248948A1 (en) * 2009-05-14 2011-12-01 Gilead Sciences, Inc. Ranolazine for the treatment of CNS disorders

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567264A (en) * 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
ATE223218T1 (de) * 1989-06-23 2002-09-15 Syntex Llc Ranolazin und verwandte piperazine zum schutz der skelettmuskulatur
US5455045A (en) * 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
US20030077229A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs
US6541479B1 (en) * 1997-12-02 2003-04-01 Massachusetts College Of Pharmacy Calcium channel blockers
US6897305B2 (en) * 1998-06-08 2005-05-24 Theravance, Inc. Calcium channel drugs and uses
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
US6734192B1 (en) * 1999-08-23 2004-05-11 Mp-1 Inc. Treatment of viral infections
US20050245502A1 (en) * 1999-08-23 2005-11-03 Phoenix Biosciences Treatments for viral infections
US6803457B1 (en) * 1999-09-30 2004-10-12 Pfizer, Inc. Compounds for the treatment of ischemia
MXPA02007639A (es) * 2000-02-18 2004-08-23 Cv Therapeutics Inc Inhibidores de la oxidacion parcial de los acidos grasos en el tratamiento de la falla cardiaca congestiva.
US20030220312A1 (en) * 2000-05-11 2003-11-27 G.D. Searle & Co. Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of cardiovascular disorders
AU2001277938A1 (en) * 2000-07-21 2002-02-05 Cv Therapeutics, Inc. Method for treating angina
WO2002009761A2 (en) * 2000-07-27 2002-02-07 Pharmacia Corporation Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
GB0028414D0 (en) * 2000-11-22 2001-01-03 Univ Leeds Flush preservation solution
US6423705B1 (en) * 2001-01-25 2002-07-23 Pfizer Inc. Combination therapy
KR20040025889A (ko) * 2001-01-26 2004-03-26 쉐링 코포레이션 혈관성 질환을 치료하기 위한 스테롤 흡수 억제제와심혈관성 제제의 조합물
DE10126328A1 (de) * 2001-05-30 2002-12-12 Infineon Technologies Ag Integrierte, abstimmbare Kapazität
US20030220310A1 (en) * 2001-07-27 2003-11-27 Schuh Joseph R. Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
US20050250676A1 (en) * 2001-11-19 2005-11-10 Aventis Pharma Deutschland Gmbh Method of activating insulin receptor substrate-2 to stimulate insulin production
WO2003066035A2 (en) * 2002-02-08 2003-08-14 Smithkline Beecham Corporation Compounds for inhibiting insulin secretion and methods related thereto
DK1764118T3 (da) * 2002-02-15 2010-11-08 Gilead Palo Alto Inc Polymer-coating til medicinske anordninger
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
WO2003099281A2 (en) * 2002-05-21 2003-12-04 Cv Therapeutics, Inc. Administration of a partial fatty acid inhibitor such as ranolazine for the treatment of diabetes
ATE362108T1 (de) * 2003-03-05 2007-06-15 Metabolex Inc Verfahren und zusammensetzungen zur diagnose und behandlung von diabetes und assoziierten krankheiten mit beta-trp (mtr1 / ltrpc5 / trpm5)
US8071645B2 (en) * 2003-06-12 2011-12-06 The Regents Of The University Of Colorado Systems and methods for treating human inflammatory and proliferative diseases and wounds, with fatty acid metabolism inhibitors and/or glycolytic inhibitors
US20050074425A1 (en) * 2003-07-02 2005-04-07 Polycord, Inc. Method for delivering polymerized therapeutic agent compositions and compositions thereof
US7060723B2 (en) * 2003-08-29 2006-06-13 Allergan, Inc. Treating neurological disorders using selective antagonists of persistent sodium current
ES2258365B1 (es) * 2003-10-03 2007-12-01 Lacer, S.A. Derivados de disulfuro, sulfuro, sulfoxido y sulfona de azucares ciclicos y sus usos.
US7510710B2 (en) * 2004-01-08 2009-03-31 The Regents Of The University Of Colorado Compositions of UCP inhibitors, Fas antibody, a fatty acid metabolism inhibitor and/or a glucose metabolism inhibitor
CA2568134A1 (en) * 2004-05-24 2005-12-08 New York University Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
EP1809289A1 (en) * 2004-11-09 2007-07-25 Cv Therapeutics, Inc. Use ranolazine in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure
MX2007008162A (es) * 2005-01-06 2007-07-24 Cv Therapeutics Inc Formulaciones farmaceuticas de liberacion prolongada que contienen ranolazina.
AU2006223212A1 (en) * 2005-03-11 2006-09-21 Hong Kong Nitric Oxide Limited Combination therapy for endothelial dysfunction, angina and diabetes
US20080153840A1 (en) * 2006-12-21 2008-06-26 Luiz Belardinelli Reduction of cardiovascular symptoms
EP2117509A1 (en) * 2007-02-13 2009-11-18 CV Therapeutics Inc. Use of ranolazine for the treatment of cardiovascular diseases
EP2117550A1 (en) * 2007-02-13 2009-11-18 CV Therapeutics Inc. Use of ranolazine for the treatment of non-coronary microvascular diseases
WO2008101008A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of coronary microvascular diseases
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
WO2008116083A1 (en) * 2007-03-22 2008-09-25 Cv Therapeutics, Inc. Use of ranolazine for elevated brain-type natriuretic peptide
US20100130436A1 (en) * 2008-11-25 2010-05-27 Gilead Palo Alto, Inc. Co-administration of ranolazine and cardiac glycosides
AU2010248948A1 (en) * 2009-05-14 2011-12-01 Gilead Sciences, Inc. Ranolazine for the treatment of CNS disorders

Also Published As

Publication number Publication date
CN101896181A (zh) 2010-11-24
ES2402675T8 (es) 2013-06-25
WO2008150565A3 (en) 2009-04-02
IL202493A0 (en) 2011-07-31
EP2170333B1 (en) 2013-02-20
WO2008150565A2 (en) 2008-12-11
ECSP099828A (es) 2010-01-29
AU2008260480A1 (en) 2008-12-11
US20080299195A1 (en) 2008-12-04
KR20100033490A (ko) 2010-03-30
ZA200908657B (en) 2010-08-25
HK1143066A1 (en) 2010-12-24
ES2402675T3 (es) 2013-05-07
CA2689633A1 (en) 2008-12-11
EP2170333A2 (en) 2010-04-07

Similar Documents

Publication Publication Date Title
EA200971073A1 (ru) Применение ранолазина при повышенном уровне натрийуретического пептида мозгового типа
EA201691347A2 (ru) Терапия глатирамером ацетатом с низкой кратностью
CY1115180T1 (el) Επιλογες θεραπειας για τη νοσο του fabry
AR071810A1 (es) Metodo de tratamiento de la disnea asociada con la insuficiencia cardiaca aguda. relaxina h2. uso.
EA201170669A1 (ru) Лечение пирфенидоном пациентов с атипичной функцией печени
ATE553772T1 (de) Verwendung von lvv-hämorphin-6 und optional af12198 als therapeutische(s) mittel
UA107578C2 (uk) Комбінована терапія при лікуванні діабету
AR086356A1 (es) Combinacion farmaceutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2
RU2015134581A (ru) Доноры нитроксила с улучшенным терапевтическим индексом
RU2013123646A (ru) Комбинированная композиция
AR043259A1 (es) Metodo para el tratamiento de insuficiencia cardiaca severa y medicamento para ello
ATE516366T1 (de) Regulierte aptamer-therapeutika
RU2009101026A (ru) Применение тимозина-альфа-1 для получения лекарственного средства для лечения злокачественной меланомы на iv стадии
BR0213823A (pt) Método de administração de um peptìdeo timosina alfa 1
CY1116171T1 (el) Χρηση ακετυλο-l-καρνιτινης για την παρασκευη φαρμακου για τη θεραπευτικη αγωγη του νευροπαθητικου πονου σε διαβητικους ασθενεις
EP1622450A4 (en) PROCESS FOR PROMOTING UNINTERRUPTED SLEEP BY ADMINISTERING TROPIUM CHLORIDE
EA201000739A1 (ru) Новое медицинское применение солей 3-(2,2,2-триметилгидразиниум)пропионата
ATE495750T1 (de) Sulfatide zur behandlung von autoimmunkrankheiten
RU2013148539A (ru) Алиспоривир для лечения инфекции вируса гепатита с
Kimmig et al. Successful Outpatient Transition from Intravenous Treprostinil to Oral Selexipag
ATE542529T1 (de) Verwendung von l-carnitin zur behandlung von herz-kreislauf-erkrankungen
RU2007129578A (ru) Способ комплексного лечения остроконечных кондилом урогенитального тракта
Sakabe Peginterferon-α
RU2005119213A (ru) Способ лечения больных с затяжной пневмонией с применением препарата "рузам"
MD3987C2 (ru) Приминение Диосмина для лечения прогрессирующего цирроза печени сопутствующего с сердечной недостаточностью